Artiva Biotherapeutics, Inc.
ARTV
$11.78
$0.564.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -100.00% | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -100.00% | -100.00% |
| SG&A Expenses | 8.18% | 17.81% | 31.51% | 48.08% | 37.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.82% | 32.98% | 35.47% | 33.53% | 24.46% |
| Operating Income | -22.82% | -33.48% | -41.25% | -156.22% | -172.84% |
| Income Before Tax | -21.40% | -28.29% | -29.38% | -131.51% | -176.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.40% | -28.29% | -29.23% | -131.00% | -176.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.40% | -28.29% | -29.23% | -131.00% | -176.21% |
| EBIT | -22.82% | -33.48% | -41.25% | -156.22% | -172.84% |
| EBITDA | -23.37% | -34.48% | -42.72% | -168.03% | -187.66% |
| EPS Basic | 85.46% | 91.60% | 94.10% | 91.79% | 24.12% |
| Normalized Basic EPS | 85.21% | 91.43% | 95.24% | 93.87% | 48.27% |
| EPS Diluted | 85.46% | 91.60% | 95.35% | 95.11% | 58.87% |
| Normalized Diluted EPS | 85.21% | 91.43% | 95.24% | 94.99% | 58.98% |
| Average Basic Shares Outstanding | 43.36% | 117.74% | 357.58% | 2,742.15% | 2,020.85% |
| Average Diluted Shares Outstanding | 43.36% | 117.74% | 357.58% | 879.02% | 629.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |